TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18377382

Group type: EXPERIMENTAL
Intervention: Oral triptans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triptans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effervescent aspirin
Number of subjects: 0
Study: 15946914

Group type: EXPERIMENTAL
Intervention: Microemulsion of cyclosporine, mycophenolatesodium, steroids and basiliximab
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Increased cyclosporine (CsA) dose
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Decreased CsA dose after 14 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: C2 monitoring
Number of subjects: 41
Study: 12795353

Group type: EXPERIMENTAL
Intervention: Serrated, parallel‐sided, cast post and core
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Serrated, parallel‐sided, prefabricated post and resin‐composite core
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carbon‐fiber‐reinforced (CFC) post and resin‐composite core
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ceramic post and resin‐composite core
Number of subjects: 40
Study: 10472212

Group type: EXPERIMENTAL
Intervention: Acute preoperative normovolaemic haemodilution (NHD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no NHD)
Number of subjects: 0
Study: 9086872

Group type: EXPERIMENTAL
Intervention: Tracing, drafting, and measurement error for TM joint space analysis (TM-JSA)
Number of subjects: 16
Study: 1651894

Group type: EXPERIMENTAL
Intervention: Neurolept anaesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both anaesthesia types
Number of subjects: 26
Study: 6810015

Group type: EXPERIMENTAL
Intervention: Long-acting insulin preparation given once daily at variable doses
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31496287

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard diet for 3 months
Number of subjects: 60
Study: 31097413

Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity counseling (TC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Education (EC)
Number of subjects: 64
Study: 27997274

Group type: EXPERIMENTAL
Intervention: Psychoeducative programme (8 sessions, 2 hours each) with 2-year outpatient follow-up
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (2-year outpatient follow-up only)
Number of subjects: 80
Study: 25913664

Group type: EXPERIMENTAL
Intervention: BMS-582949 (100 mg once daily)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg once daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25004983

Group type: EXPERIMENTAL
Intervention: Decision aid plus patient navigation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 300
Study: 21295198

Group type: EXPERIMENTAL
Intervention: Warfarin management communication protocol using SBAR approach
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control group (standard communication)
Number of subjects: 435
Study: 19390548

Group type: EXPERIMENTAL
Intervention: Addition of etoposide to cyclophosphamide and ifosfamide in patients with large, localized tumors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide and ifosfamide
Number of subjects: 0
Study: 17342644

Group type: EXPERIMENTAL
Intervention: Multifaceted guideline-implementation strategy tailored to baseline performance
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 1906
Study: 15261316

Group type: EXPERIMENTAL
Intervention: MgSO4 (50 mg kg(‐1) in 100 mL saline, followed by 50 mL hr(‐1) infusion of MgSO4 (15 mg kg(‐1) hr(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (equal volume to MgSO4)
Number of subjects: 50
Study: 11389256

Group type: EXPERIMENTAL
Intervention: Nitric oxide treatment for PPHN
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no nitric oxide treatment)
Number of subjects: 83
Study: 9244079

Group type: EXPERIMENTAL
Intervention: Subcuticular suture (3/0 prolene)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metal clips (Michel clips)
Number of subjects: 80
Study: 8302758

Group type: EXPERIMENTAL
Intervention: Ultrasound massage (3.0 MHz, 1.0 W/cm2 continuous output) for 5 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo massage (0 MHz) for 5 min
Number of subjects: 10
Study: 3103731

Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic sphincterotomy and stone clearance (group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgery alone (group 2)
Number of subjects: 120
Study: 29297698

Group type: EXPERIMENTAL
Intervention: Napabucasin combined with paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with paclitaxel
Number of subjects: 0
Study: 26376350

Group type: EXPERIMENTAL
Intervention: Tofacitinib (0.5, 3, 10, or 15 mg twice daily)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 194
Study: 24091694

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1521 vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22842667

Group type: EXPERIMENTAL
Intervention: PTH (1‐34) 20 μg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PTH (1‐84) 100 μg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated osteoporotic women)
Number of subjects: 30
Study: 20226809

Group type: COMPARATOR
Intervention: Written materials
Number of subjects: 96

Group type: COMPARATOR
Intervention: Written materials plus a one-page form for dietary planning
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Written materials, one-page form, and telephone counseling from a dietitian
Number of subjects: 96
Study: 18937830

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15986951

Group type: EXPERIMENTAL
Intervention: Bleached groups treated with peroxide bleaching regimens
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unbleached control group
Number of subjects: 70
Study: 11986563

Group type: EXPERIMENTAL
Intervention: static with motion correction (MC) only
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: gated with MC only
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: static with MC plus blur correction plus AC (combined corrections [CC])
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: gated with CC
Number of subjects: 66
Study: 12873166

Group type: EXPERIMENTAL
Intervention: HPV triage testing
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Immediate colposcopy
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Cytologic follow-up
Number of subjects: 5050

Group type: COMPARATOR
Intervention: HPV DNA testing by Hybrid Capture 2
Number of subjects: 5050
Study: 9653864

Group type: EXPERIMENTAL
Intervention: High-dose danazol (600 mg daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose danazol (200 mg daily) plus placebo tablets
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 7664720

Group type: EXPERIMENTAL
Intervention: Biologically fermented milk product (200 ml/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo product (200 ml/day)
Number of subjects: 58
Study: 2474017

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L5HTP; 100 mg qid) with carbidopa (C; 50 mg qid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 965302

Group type: EXPERIMENTAL
Intervention: Breath holding (BH) with 100% O2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Breath holding (BH) with 21% O2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Breath holding (BH) with 12% O2
Number of subjects: 5
Study: 31014382

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 71
Study: 29107949

Group type: EXPERIMENTAL
Intervention: Endocervical brush (ECB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endocervical curette (ECC)
Number of subjects: 200
Study: 26580831

Group type: EXPERIMENTAL
Intervention: Topical glycerol trinitrate (2g once a day for 3 days before laser sessions)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 23229188

Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5 mg/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cyclosporine (2.5 mg/kg/day)
Number of subjects: 40
Study: 21818510

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray
Number of subjects: 81

Group type: COMPARATOR
Intervention: Vehicle spray
Number of subjects: 81
Study: 19451425

Group type: EXPERIMENTAL
Intervention: Irinotecan/LV5FU2
Number of subjects: 2094

Group type: COMPARATOR
Intervention: LV5FU2 alone
Number of subjects: 2094
Study: 16461867

Group type: EXPERIMENTAL
Intervention: Primary care, office‐based, computer‐assisted diet and PA assessment and stage‐based goal setting followed by brief health care provider counseling and 12 months of monthly mail and telephone counseling
Number of subjects: 878

Group type: COMPARATOR
Intervention: Sun protection condition
Number of subjects: 878
Study: 15056197

Group type: EXPERIMENTAL
Intervention: Development of numerical estimation on 0‐to‐100 number lines
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Exposure to relevant experience
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Individual differences in number‐line estimation
Number of subjects: 3
Study: 11787317

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 29

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 29
Study: 9287262

Group type: EXPERIMENTAL
Intervention: 60 mmol/day potassium supplement for four weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 48 mmol/day potassium supplement for four months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8346578

Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS) therapy - intravenous methylprednisolone 2 mg/kg bodyweight daily for ten days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cotrimoxazole (standard treatment)
Number of subjects: 59
Study: 3555175

Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg three times a day for two weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30679318

Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo plus exemestane
Number of subjects: 724
Study: 27646064

Group type: EXPERIMENTAL
Intervention: Organ Care System
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 38
Study: 26383218

Group type: EXPERIMENTAL
Intervention: Group Assertiveness Training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 57
Study: 22927230

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.4 ng/mL (group SL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.8 ng/mL (group SH)
Number of subjects: 42
Study: 21353695

Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg subcutaneous every 4 weeks)
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Zoledronic acid (4 mg intravenous every 4 weeks)
Number of subjects: 1904

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 1904
Study: 19608171

Group type: EXPERIMENTAL
Intervention: Supraphysiologic (0.2 mg/d transdermal E(2) and vaginal micronized E(2))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Physiologic (0.2 mg/d transdermal E(2))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Subphysiologic (no exogenous E(2) treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 18
Study: 17051443

Group type: EXPERIMENTAL
Intervention: Social Communication Assessment for Toddlers with Autism (SCATA)
Number of subjects: 0
Study: 15321697

Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (high dose) 480/240 mg/d
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (low dose) 320/160 mg/d
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/d
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (high dose)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (low dose)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: All active treatments (Quinidine + Verapamil high dose, low dose, Sotalol)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil and Sotalol
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil
Number of subjects: 1033
Study: 11446451

Group type: EXPERIMENTAL
Intervention: Cataract surgery in glaucoma participants
Number of subjects: 3271

Group type: EXPERIMENTAL
Intervention: Cataract surgery in non-glaucoma participants
Number of subjects: 3271

Group type: COMPARATOR
Intervention: Non-operated eyes in glaucoma participants
Number of subjects: 3271

Group type: COMPARATOR
Intervention: Non-operated eyes in non-glaucoma participants
Number of subjects: 3271
Study: 9671326

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg three times weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study: 7803947

Group type: EXPERIMENTAL
Intervention: Amitriptyline, dothiepin, mianserin, trazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nortriptyline, maprotiline, amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors
Number of subjects: 0
Study: 3288951

Group type: EXPERIMENTAL
Intervention: Oxybutynin 10 mg at suppertime for 28 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 30
Study: 30035576

Group type: EXPERIMENTAL
Intervention: Nicotine deprivation (12-24 hr abstinence)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continued ad lib smoking
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Nicotine deprivation (12-24 hr abstinence) among smokers who reported no pain at baseline
Number of subjects: 137
Study: 28821940

Group type: EXPERIMENTAL
Intervention: Flexible endoscopic evaluation of swallowing with endoscope insertion
Number of subjects: 37

Group type: COMPARATOR
Intervention: Videofluoroscopy without endoscope insertion
Number of subjects: 37
Study: 26322666

Group type: EXPERIMENTAL
Intervention: PI-1000
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: PI-30,000
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: NNRTI-1000
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: NNRTI-30,000
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: abacavir + lamivudine
Number of subjects: 267
Study: 24082090

Group type: EXPERIMENTAL
Intervention: Kinematic mental simulations
Number of subjects: 0
Study: 20411996

Group type: EXPERIMENTAL
Intervention: MPA 10 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: CEE 0.6 mg/day
Number of subjects: 33
Study: 18182939

Group type: EXPERIMENTAL
Intervention: Irbesartan and estradiol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Irbesartan alone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Estradiol and placebo
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo/placebo
Number of subjects: 51
Study: 16582549

Group type: EXPERIMENTAL
Intervention: QUANTEC treatment for 3 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no treatment during first phase)
Number of subjects: 34
Study: 15806847

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (30% protein)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet (55% carbohydrate)
Number of subjects: 11
Study: 11061470

Group type: EXPERIMENTAL
Intervention: Budesonide 64 microg aqueous nasal spray
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Budesonide 256 microg aqueous nasal spray
Number of subjects: 25
Study: 8655889

Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: salbutamol 200 micrograms twice daily
Number of subjects: 30
Study: 1417196

Group type: EXPERIMENTAL
Intervention: New polyvalent melanoma cell vaccine (MCV)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Historical database of previous immunotherapy and other treatments
Number of subjects: 136
Study: 2864709

Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam per day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.5 mg fluspirilene per week
Number of subjects: 45
Study: 31012968

Group type: EXPERIMENTAL
Intervention: Primary intervention group (Garmin Vivofit 2 + behavioral feedback + goal-setting + 5 health coaching sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist control group (Garmin Vivofit 2 only)
Number of subjects: 80
Study: 30266894

Group type: EXPERIMENTAL
Intervention: low‐flu/val (10 mg/20 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 27514243

Group type: EXPERIMENTAL
Intervention: Five year screening and lifestyle counselling programme (n=11,629)
Number of subjects: 59616

Group type: COMPARATOR
Intervention: Control group (n=47,987)
Number of subjects: 59616
Study: 25236838

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (AA)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 119
Study: 22381137

Group type: EXPERIMENTAL
Intervention: Nutrition on the Go intervention (decreased energy content of school breakfasts, increased fruits and vegetables, increased physical activity, and water consumption)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Control group (standard school breakfast without intervention)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Interaction between intervention and stage
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Girls in the intervention group
Number of subjects: 1020
Study: 20855047

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both Sertraline and CBT (COMB)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) without family history of OCD
Number of subjects: 112
Study: 17939880

Group type: EXPERIMENTAL
Intervention: From Home To Operation (FHTO)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional ward procedures
Number of subjects: 47
Study: 14752209

Group type: COMPARATOR
Intervention: Growth Hormone (GH) replacement therapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Thyroxine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ACTH insufficiency management
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Sex hormone replacement therapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 112
Study: 11490232

Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Tumor volume measurement
Number of subjects: 168
Study: 9207222

Group type: EXPERIMENTAL
Intervention: Chloral hydrate
Number of subjects: 0
Study: 8135108

Group type: EXPERIMENTAL
Intervention: Seaprose S (30 mg tablets, 3 tab/day)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Nimesulide (100 mg, 2 tab/day)
Number of subjects: 320
Study: 3309827

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 581

Group type: COMPARATOR
Intervention: Josamycin
Number of subjects: 581

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 581
Study: 30932776

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (330 mg) and vitamin D3 (0.005 mg or 200 IU) per day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 29439278

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: M-NBI
Number of subjects: 343

Group type: COMPARATOR
Intervention: Comparison of M-NBI and chromoendoscopy
Number of subjects: 343
Study: 28009335

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 40
Study: 24332577

Group type: EXPERIMENTAL
Intervention: MI+HealthCall
Number of subjects: 139

Group type: COMPARATOR
Intervention: MI-only
Number of subjects: 139
Study: 23516319

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 106

Group type: COMPARATOR
Intervention: 10-Hz rTMS
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nonmotor symptoms (all groups)
Number of subjects: 106
Study: 20197486

Group type: EXPERIMENTAL
Intervention: laropiprant 40 mg for 10 days + single-dose digoxin 0.5 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: single-dose digoxin 0.5 mg
Number of subjects: 13
Study: 19022184

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 127

Group type: COMPARATOR
Intervention: No PTA (control)
Number of subjects: 127
Study: 16822131

Group type: EXPERIMENTAL
Intervention: Orthographically related nonword primes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orthographically related word primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime and target sharing a neighbor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-N nonword foils
Number of subjects: 0
Study: 12814902

Group type: EXPERIMENTAL
Intervention: Ethanol (0.4 g/kg, 22‐28 g) twice daily for 8 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (juice)
Number of subjects: 9
Study: 11855255

Group type: EXPERIMENTAL
Intervention: Phased outcome clinical pathways for SCIs
Number of subjects: 0